Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 27

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 27
---
, are “independent” as that term is defined under the Nasdaq for purposes of serving on our board of directors and those committees of our board of directors upon which each such director sits. Additionally, Burton Malkiel, who did not stand for reelection at our 2024 annual general meeting, was an independent director during the period he served in 2024 under the standards applicable to our continuing directors and our director nominees. The independent members of our board of directors hold, and will continue to hold, separate regularly scheduled executive session meetings at which only independent directors are present. Chair of the Board and Lead Independent Director Mr. Winningham served as our chair of the board of directors and our principal executive officer and Mr. Mitchell served as our lead independent director until October 2024. Prior to October 2024, our lead independent director provided a source of leadership for the board of directors that was complementary to that of Mr. Winningham as chairman of the board of directors and helped to ensure the effective independent functioning of the board of directors in its oversight responsibilities. In October 2024, as part of its ongoing review of its corporate governance policies, the board of directors separated the roles of chair 18 TABLE OF CONTENTS of the board of directors and chief executive officer. The board of directors determined that the separation of these roles would allow management to sharpen its focus on operational goals. The board of directors elected Susannah Gray to the role of chair of the board of directors, while Mr. Winningham continued his role as a member of the board of directors and our principal executive officer. Our Board of Directors Guidelines on Significant Corporate Governance Issues (“Corporate Governance Guidelines”) are posted on the Investor Relations portion of our website at www.theravance.com. Board Committees Our board of directors has established an audit committee, a compensation committee and a nominating/ corporate governance committee. Our board of directors and its committees set schedules for meetings throughout the year and can also hold special meetings and act by written resolutions from time to time, as appropriate. Our board of directors has delegated various responsibilities and authority to its committees as generally described below. The committees regularly report on their activities and actions to the full board of directors. Each member of each of our compensation, nominating/corporate governance and audit committees qualifies as an independent director in accordance with Nasdaq listing standards. Each committee of our board of directors has a written charter approved by our board of directors. Copies of each charter are posted on the Investor Relations portion of our website at www.theravance